ScreenerHero
IRLAB-AIRLAB Therapeutics AB (publ)
STO · SE · Healthcare · Biotechnology · irlab.se
1.718SEK+0.12%Mkt Cap: 24.07M $P/E: —

IRLAB Therapeutics AB (publ) discovers and develops drugs for the treatment of Parkinson's disease and other central nervous system (CNS) disorders in the United States. The company develops Mesdopetam (IRL790), which ha…

Industry Peers

Biotechnology
Screen all
VX1
Vertex Pharmaceuticals Incorporated
$130.23BUSDP/E 32.1
VRTX
Vertex Pharmaceuticals Incorporated
$139.84BUSDP/E 32.2
REGN
Regeneron Pharmaceuticals, Inc.
$85.11BUSDP/E 20.4
MRNA
Moderna, Inc.
$69.62BUSD
ARGX
argenx SE
$61.34BUSDP/E 39.8
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$46.01BUSD
ONC
BeOne Medicines AG
$41.76BUSDP/E 66.2
RPRX
Royalty Pharma Plc Class A
$35.67BUSDP/E 33.2
ALNY
Alnylam Pharmaceuticals, Inc.
$32.46BUSDP/E 42.3
INSM
Insmed Incorporated
$28.53BUSD
22UA
BioNTech SE
$26.14BUSD
INCY
Incyte Corporation
$25.79BUSDP/E 16.2
GMAB
Genmab A/S
$20.83BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$17.03BUSDP/E 20.0
BBIO
BridgeBio Pharma, Inc.
$16.41BUSD
EXEL
Exelixis, Inc.
$13.48BUSDP/E 17.1
BMRN
BioMarin Pharmaceutical Inc.
$13.42BUSDP/E 187.4
CORT
Corcept Therapeutics Incorporated
$12.87BUSDP/E 264.5

Key Statistics

Company
Market Cap24.07M $
Enterprise Value11.67M $
Revenue (TTM)8.84M $
Gross Profit-425.17K $
Net Income (TTM)-10.52M $
Revenue/Share0.1187 USD
Last Price1.718 SEK
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees31
CountrySE
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-13.20
PEG—
EV/EBITDA-2.60
EV/Revenue1.32
P/S2.72
P/B3.66
EPS (TTM)-0.86
EPS (Forward)-0.13
52W Range
1.17028% of range3.150
52W High3.150 SEK
52W Low1.170 SEK
Profitability
Gross Margin-4.81%
Oper. Margin27.26%
EBITDA Margin-50.71%
Profit Margin-191.45%
ROE-358.13%
ROA-78.13%
Growth
Revenue Growth802.80%
Earnings Growth—
Cash Flow & Leverage
Operating CF-5.28M $
CapEx (TTM)—
FCF Margin-78.30%
FCF Yield-28.77%
Net Debt-2.27M $
Net Debt/EBITDA0.51
Balance Sheet
Debt/Equity0.98
Current Ratio0.88
Quick Ratio0.88
Book Value/Sh0.4690 SEK
Cash/Share0.5980 SEK
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 SEK
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split5:1
Split DateMay 28, 2019
Analyst Consensus
Rating—
Target (Mean)7.500 SEK
Upside (mean)+336.6%
Target Range7.500 SEK – 7.500 SEK
# Analysts1
Ownership
Shares Out.146.38M
Float68.45M
Insiders16.52%
Institutions18.14%
Technical
SMA 501.348 (+27.5%)
SMA 2001.612 (+6.6%)
Beta0.53
S&P 52W Chg18.16%
Avg Vol (30d)885.82K
Avg Vol (10d)2.33M
Technical Indicators
RSI (14)74.2
MACD0.1027
MACD Signal0.0646
MACD Hist.+0.0380
BB Upper1.768 SEK
BB Middle1.427 SEK
BB Lower1.087 SEK
BB Width47.74%
ATR (14)0.0858 SEK
Vol Ratio (20d)0.38x